MAPT and Alzheimer disease: Collectively, these findings add to the growing evidence that supports the notion that boosting brain levels of leptin not only counteracts Aβ- and tau-driven synaptic dysfunction but also that targeting the leptin system may have therapeutic value in treating AD.